Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, March 18, 2021
[ Thu, Mar 18th 2021
] - WOPRAI
[ Thu, Mar 18th 2021
] - WOPRAI
Wed, March 17, 2021
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
Gregory Renza Maintained (APRE) at Hold with Decreased Target to $160 on, Mar 17th, 2021
Gregory Renza of RBC Capital, Maintained "Aprea Therapeutics, Inc." (APRE) at Hold with Decreased Target from $200 to $160 on, Mar 17th, 2021.
Gregory has made no other calls on APRE in the last 4 months.
There are 2 other peers that have a rating on APRE. Out of the 2 peers that are also analyzing APRE, 1 agrees with Gregory's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Decreased Target to $680 on, Wednesday, December 16th, 2020
This is the rating of the analyst that currently disagrees with Gregory
- Esther Hong of "Berenberg" Initiated at Strong Buy and Held Target at $740 on, Wednesday, December 16th, 2020
